Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)
Launched by AURA BIOSCIENCES · Mar 3, 2022
Trial Information
Current as of July 01, 2025
Terminated
Keywords
ClinConnect Summary
Up to approximately 45 patients who are planned to receive plaque radiotherapy for the treatment of IL/CM based on the expert judgment of the Investigator are planned to be enrolled.
Gender
ALL
Eligibility criteria
- • Have per the investigator's expert clinical judgment, a clinical diagnosis of primary indeterminate lesion or choroidal melanoma based on the clinical history, ophthalmic examination, fundus photography and conventional ocular ultrasound.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company focused on developing innovative therapies for ocular oncology. Their proprietary platform leverages a unique approach to target and eradicate cancer cells while preserving healthy tissue, with a primary emphasis on treating rare eye cancers such as uveal melanoma. Committed to advancing patient care, Aura Biosciences aims to bring transformative solutions to the field of ophthalmology through rigorous clinical trials and a dedication to scientific excellence.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Royal Oak, Michigan, United States
Bellaire, Texas, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Madison, Wisconsin, United States
Nashville, Tennessee, United States
Patients applied
Trial Officials
Medical Monitor
Study Director
Aura Biosciences, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials